Zobrazeno 1 - 10
of 354
pro vyhledávání: '"Lesley J. Scott"'
Autor:
Susan J. Keam, Lesley J. Scott
Publikováno v:
Drugs. 81:277-282
Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68b655713aa8c40bae486a8be10d470b
https://doi.org/10.1007/s40265-020-01463-0
https://doi.org/10.1007/s40265-020-01463-0
Autor:
Lesley J. Scott
Publikováno v:
Targeted Oncology. 15:791-799
Oral darolutamide (Nubeqa™) is a novel second-generation, nonsteroidal, selective androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). In the pivotal multinational, phase 3 AR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19d66095d363f96c90eddffc25557f40
https://doi.org/10.1007/s11523-020-00779-x
https://doi.org/10.1007/s11523-020-00779-x
Autor:
Lesley J. Scott
Publikováno v:
CNS Drugs
Oral siponimod (Mayzent®), a next-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary progressive multiple sclerosis (SPMS), with specific indications varyi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f952a6f8c14bb52311654fd96290b47
https://doi.org/10.1007/s40263-020-00771-z
https://doi.org/10.1007/s40263-020-00771-z
Autor:
Lesley J. Scott
Publikováno v:
Drugs. 80:1465-1475
Secondary cardiovascular (CV) prevention in patients with vascular disease [e.g. coronary (CAD) and peripheral (PAD) artery disease] is crucial and typically involves antiplatelet therapy with aspirin; however, managing residual ischaemic and bleedin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ffec7b4e6b67193d5675b08331bfb39
https://doi.org/10.1007/s40265-020-01397-7
https://doi.org/10.1007/s40265-020-01397-7
Autor:
Connie Kang, Lesley J. Scott
Publikováno v:
Molecular Diagnosis & Therapy. 24:487-495
Voretigene neparvovec (Luxturna®), a recombinant adeno-associated virus vector-based gene therapy, delivers a functioning copy of the human retinal pigment epithelium-specific 65 kDa (RPE65) gene into retinal cells of patients with reduced or absent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4abc32ea85c470fffd9e426fce6efaa5
https://doi.org/10.1007/s40291-020-00475-6
https://doi.org/10.1007/s40291-020-00475-6
Autor:
Lesley J. Scott
Publikováno v:
Drugs. 80:741-746
The orally disintegrating tablet (ODT) formulation of rimegepant (NURTEC ODT®) is a small molecule, highly-selective, calcitonin gene-related peptide antagonist that was developed by Biohaven Pharmaceutical Holding Company Ltd as an acute treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a63e27db0924a89a36208a4edf5b593
https://doi.org/10.1007/s40265-020-01301-3
https://doi.org/10.1007/s40265-020-01301-3
Autor:
Arnold Lee, Lesley J. Scott
Publikováno v:
BioDrugs. 34:235-244
Certolizumab pegol (Cimzia®) is a PEGylated, Fab′-only, recombinant humanized antibody against TNF-α. Subcutaneous certolizumab pegol is indicated for the treatment of various immune-mediated inflammatory diseases (IMIDs), including moderate to s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f91f1ced0450420d82259edbb257d30b
https://doi.org/10.1007/s40259-020-00416-z
https://doi.org/10.1007/s40259-020-00416-z
Autor:
Lesley J. Scott
Publikováno v:
Drugs & Therapy Perspectives. 36:97-105
Apalutamide (ERLEADA®), a next-generation androgen receptor (AR) inhibitor, is approved in several countries, including those of the EU and in the USA, for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). In the pivotal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0ea0e59810d5b8e3c9de932515f4c43
https://doi.org/10.1007/s40267-020-00707-z
https://doi.org/10.1007/s40267-020-00707-z
Autor:
Lesley J. Scott
Publikováno v:
Drugs. 80:197-208
Subcutaneous dulaglutide (Trulicity®) is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7cbdf26b72d9a5feb67c21ff3010ddc
https://doi.org/10.1007/s40265-020-01260-9
https://doi.org/10.1007/s40265-020-01260-9
Autor:
Lesley J. Scott
Publikováno v:
Drugs. 79:1905-1909
Topical trifarotene (Aklief®) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris. In October 2019 trifaroten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5661cdbe4a12160085c7f7633dd01de8
https://doi.org/10.1007/s40265-019-01218-6
https://doi.org/10.1007/s40265-019-01218-6